ArticleMolecular therapy : the journal of the American Society of Gene Therapy2012
Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Potency-enhancing mutations in E3-19K and i-leader increase the cytolytic activity of the PH20/Molecular therapy. Oncology · 2026Article
- The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.Nature communications · 2025Article
- Preclinical studies of the triazolo[1,5-Acta pharmaceutica Sinica. B · 2022Article
- The Mechanisms of lncRNA-Mediated Multidrug Resistance and the Clinical Application Prospects of lncRNAs in Breast Cancer.Cancers · 2022Review
- A systematic analysis on the clinical safety and efficacy of onco-virotherapy.Molecular therapy oncolytics · 2021Article
- Oncolytic viruses for cancer immunotherapy.Journal of hematology & oncology · 2020Review
- Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.Oncotarget · 2018Article
- Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.Oncoimmunology · 2016Article
- The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy.Frontiers in pharmacology · 2016Review
- T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.Current gene therapy · 2013Review
- Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment.Journal of translational medicine · 2013Article
- HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.Cancer gene therapy · 2013Article
- Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Oncolytic virotherapy: the questions and the promise.Oncolytic virotherapy · 2013Review
- A potential therapeutic strategy for malignant mesothelioma with gene medicine.BioMed research international · 2013Review
- Treatment of chemotherapy-refractory cancer in the advanced therapy access program.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcium channel blockers including verapamil have been proposed to enhance release and antitumor efficacy of oncolytic adenoviruses in preclinical studies but this has not been studied in humans before. Here, we studied if verapamil leads to increased replication of oncolytic adenovirus in cancer patients, as measured by release of virions from tumor cells into the systemic circulation. The study was conducted as a matched case-control study of advanced cancer patients treated with oncolytic adenoviruses with or without verapamil. We observed that verapamil increased mean virus titers present in blood after treatment (P < 0.05). The frequency or severity of adverse events was not increased, nor were cytokine responses or neutralizing antibody levels different between groups. Signs of possible treatment-related clinical benefits were observed in both groups, but there was no significant difference in responses or survival. Thus, our data suggests that the combination of verapamil with oncolytic adenoviruses is safe and well tolerated. Moreover, verapamil treatment seems to result in higher virus titers in blood, indicating enhanced overall replication in tumors. A randomized trial is needed to confirm these findings and to study if enhanced replication results in benefits to patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.